Zacks: Analysts Anticipate Aemetis, Inc. (NASDAQ:AMTX) Will Announce Quarterly Sales of $56.53 Million

Wall Street brokerages expect Aemetis, Inc. (NASDAQ:AMTX) to report $56.53 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Aemetis’ earnings, with the highest sales estimate coming in at $62.00 million and the lowest estimate coming in at $50.00 million. Aemetis posted sales of $37.33 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 51.4%. The company is scheduled to issue its next earnings results on Monday, March 21st.

On average, analysts expect that Aemetis will report full-year sales of $205.39 million for the current fiscal year, with estimates ranging from $197.00 million to $214.00 million. For the next financial year, analysts anticipate that the firm will report sales of $260.46 million, with estimates ranging from $238.00 million to $291.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Aemetis.

Aemetis (NASDAQ:AMTX) last announced its quarterly earnings data on Thursday, November 11th. The specialty chemicals company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). During the same period last year, the business earned ($0.59) earnings per share.

AMTX has been the subject of a number of research analyst reports. Zacks Investment Research cut Aemetis from a “hold” rating to a “sell” rating in a research note on Monday, November 15th. Stifel Nicolaus reissued a “buy” rating and issued a $33.00 target price (up from $31.00) on shares of Aemetis in a research note on Monday, August 23rd. HC Wainwright reissued a “buy” rating on shares of Aemetis in a research note on Monday, August 16th. Finally, Credit Suisse Group decreased their target price on Aemetis from $40.00 to $31.00 and set an “outperform” rating for the company in a research note on Monday, August 23rd. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $31.17.

Shares of Aemetis stock traded up $1.12 during trading on Thursday, reaching $18.54. 409,901 shares of the company were exchanged, compared to its average volume of 2,152,160. Aemetis has a twelve month low of $1.96 and a twelve month high of $27.44. The business has a 50-day moving average price of $18.62 and a 200-day moving average price of $13.79. The firm has a market capitalization of $616.47 million, a price-to-earnings ratio of -8.20 and a beta of -0.34.

In related news, EVP Andrew B. Foster sold 1,300 shares of the company’s stock in a transaction dated Friday, November 5th. The stock was sold at an average price of $23.00, for a total transaction of $29,900.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Andrew B. Foster sold 8,548 shares of the company’s stock in a transaction that occurred on Wednesday, September 15th. The shares were sold at an average price of $14.08, for a total value of $120,355.84. The disclosure for this sale can be found here. Insiders have sold 140,921 shares of company stock valued at $2,561,450 over the last ninety days. 14.65% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. bought a new stake in Aemetis in the first quarter valued at approximately $1,102,000. Merewether Investment Management LP raised its stake in Aemetis by 179.3% in the second quarter. Merewether Investment Management LP now owns 642,342 shares of the specialty chemicals company’s stock valued at $7,175,000 after buying an additional 412,379 shares during the period. OLD Mission Capital LLC bought a new stake in Aemetis in the second quarter valued at approximately $968,000. Marshall Wace North America L.P. raised its stake in Aemetis by 818.5% in the second quarter. Marshall Wace North America L.P. now owns 400,967 shares of the specialty chemicals company’s stock valued at $4,479,000 after buying an additional 357,312 shares during the period. Finally, DAVENPORT & Co LLC raised its stake in Aemetis by 780.4% in the second quarter. DAVENPORT & Co LLC now owns 543,177 shares of the specialty chemicals company’s stock valued at $6,067,000 after buying an additional 481,477 shares during the period. Hedge funds and other institutional investors own 47.48% of the company’s stock.

About Aemetis

Aemetis, Inc is a renewable fuels and biochemical company, which engages in the acquisition, development, and commercialization of technologies that replace traditional petroleum-based products. It operates through the North America and India geographical segments. The North America segment manages Keyes Plant in California, the cellulosic ethanol facility in Riverbank, the cluster of biogas digesters on dairies near Keyes, California, the Goodland Plant, Kansas and the research and development facility in Minnesota.

Featured Story: What is a portfolio manager?

Get a free copy of the Zacks research report on Aemetis (AMTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aemetis (NASDAQ:AMTX)

Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.